secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clearside Biomedical, Inc. (CLSDQ)
CIK:        0001539029
Form:       8-K
Filed at:   2022-03-10T23:59:59+00:00
Accession:  0000950170-22-003368
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Clearside Biomedical Q4 2021 net income $18.7M on XIPERE milestones; CLS-AX trial advances
--------------------------------------------------------------------------------

- Q4 2021 license revenue $25.7M (vs $11K in Q4 2020) from $20M in XIPERE milestones; net income $18.7M ($0.31/sh) vs net loss $7.1M.
- Full year 2021 revenue $29.6M (vs $7.9M in 2020); net income $376K ($0.01/sh) vs net loss $18.2M in 2020.
- Cash $30.4M at Dec 31, 2021 plus $10M collected in Q1 2022; expects to fund operations into Q2 2023.
- CLS-AX OASIS Phase 1/2a: Cohort 3 results expected mid-2022; new Cohort 4 planned Q2 2022 to explore higher doses.
- XIPERE launched by Bausch + Lomb in U.S. in Q1 2022 for uveitic macular edema after FDA approval Oct 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1539029/000095017022003368/0000950170-22-003368-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1539029/000095017022003368/clsd-20220310.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-003368

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer